|Articles|February 18, 2009
Treating CME with new gen NSAID
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Advertisement
Please click
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
2
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
3
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
4
FLORetina 2025: Bridging global gaps in ROP care
5









































